Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

The marketing authorisation for the Alliance's insulin glargine product is based upon a comprehensive clinical data programme, which showed it has similar efficacy and safety compared to Lantus in ...

In July 2021, the FDA approved Biocon and Viatris’ Semglee (insulin glargine-yfgn) as the first biosimilar to Lantus. Five months later, the U.S. regulator endorsed Eli Lilly’s version of the ...

In adults, insulin glargine (a long-acting insulin analog) reduces the risk of nocturnal hypoglycemia and improves control of morning blood glucose levels; however, most published studies included ...

GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus, an insulin glargine injection and Sanofi's most widely ...

Sanofi's follow-up product to its insulin blockbuster Lantus has been approved in Europe. Toujeo (insulin glargine [rDNA origin]) has been approved for the treatment of type 1 and type 2 diabetes ...

The QWINT-1 study compared efsitora to daily injections of Sanofi’s SNY Lantus (insulin glargine) for 52 weeks in T2D patients using basal insulin for the first time. The QWINT-3 study compared ...

Viatris and Biocon Biologic’s insulin glargine has received regulatory approval ... allows substitution at the pharmacy counter for Lantus(R) across the U.S. to help increase access to medicines ...

Objective — To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. Research design and ...